UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
TUCSON, Ariz., April 10, 2016 -- Accelerate Diagnostics, Inc. (“Accelerate”) announced today it will present data related to the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures while attending the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit were formerly the Accelerate ID/AST System and Blood Culture Assay Kit.
The aforementioned data can be found in the investor presentation posted at ir.axdx.com.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms. For more information about the company and its products visit www.acceleratediagnostics.com.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and "ACCELERATE PHENOTEST" logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, our projections as to when certain key business milestones may be achieved, including initiation of the trial intended to support marketing authorization by the FDA of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the commercial launch of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the potential of our technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
CONTACT Media Contact: Andrew Chasteen (520) 365 3100 [email protected] Investor Contact: Laura Pierson (520) 365 3100 [email protected]
